Afzeta 40mg Tablet

About

Afatinib, often branded as Afzeta, is an irreversible ErbB family blocker, categorized as a second-generation tyrosine kinase inhibitor (TKI). It works by irreversibly binding to and inhibiting the signaling pathways mediated by epidermal growth factor receptor (EGFR), HER2, and HER4. This comprehensive inhibition effectively blocks cell proliferation, survival, and angiogenesis, while promoting apoptosis in cancer cells that overexpress these receptors. Afatinib is primarily indicated for the treatment of specific types of non-small cell lung cancer (NSCLC) that harbor common activating EGFR mutations, such as exon 19 deletions or L858R substitutions. Its targeted action provides a significant therapeutic advantage by directly addressing the molecular drivers of the cancer, leading to improved progression-free survival and overall response rates in carefully selected patient populations. It represents a cornerstone in personalized oncology for EGFR-mutated NSCLC.

Uses

• EGFR mutation-positive non-small cell lung cancer (NSCLC)
• Advanced or metastatic NSCLC
• Squamous cell carcinoma of the lung (after platinum-based chemotherapy)
• First-line treatment for specific EGFR mutations

Directions For Use

Take orally once daily on an empty stomach, at least one hour before or two hours after food. Swallow the tablet whole with water.

Benefits

• Targets specific EGFR mutations in NSCLC.
• Improves progression-free survival in eligible patients.
• Offers an oral, convenient treatment option.
• Can be used as first-line therapy.
• Provides a targeted approach to cancer treatment.
• May lead to significant tumor shrinkage.

Side Effects

• Diarrhea
• Rash/Acneiform dermatitis
• Stomatitis
• Paronychia (nail inflammation)
• Dry skin
• Decreased appetite
• Nausea
• Vomiting
• Fatigue
• Pruritus
• Conjunctivitis
• Liver enzyme elevation

Safety Measures

• Alcohol - Limit alcohol intake as it may exacerbate gastrointestinal side effects like diarrhea or nausea. Discuss with your doctor.
• Pregnancy - Afatinib is not recommended during pregnancy due to potential fetal harm. Women of childbearing potential must use effective contraception during treatment and for at least one month after the last dose.
• Breastfeeding - Breastfeeding is not recommended during treatment with Afatinib and for at least one month after the last dose, due to potential harm to the infant.
• Liver - Use with caution in patients with pre-existing liver impairment. Regular monitoring of liver function tests is recommended, and dose adjustments may be necessary.
• Kidney - No dose adjustment is generally required for mild to moderate renal impairment. Use with caution in severe renal impairment, as data are limited.
• Lung - Patients should be monitored for new or worsening pulmonary symptoms, including interstitial lung disease (ILD), which can be a serious but rare side effect.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.